JAYPIRCA Eli Lilly Australia Pty Ltd
Product name
JAYPIRCA
Sponsor
Accepted date
Mar-2026
Active ingredients
pirtobrutinib
Summary of proposed indication
JAYPIRCA (pirtobrutinib) is proposed as a monotherapy for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Application type
A (new medicine)
Publication date
Mar-2026